Abstract:Background and Purpose: Pathological angiogenesis is a major cause of irreversible blindness in individuals with neovascular age-related macular degeneration (nAMD). Macrophages and microglia (M Phi) contribute to aberrant ocular angiogenesis. However, the role of glucose metabolism of M Phi in nAMD is still undefined. Here, we have investigated the involvement of glycolysis, driven by the kinase/phosphatase PFKFB3, in the development of choroidal neovascularization (CNV). Experimental Approach: CNV was induced in mice with laser photocoagulation. Choroid/retinal pigment epithelium (RPE) complexes and M Phi were isolated for analysis by qRT-PCR, western blot, flow cytometry, immunostaining, metabolic measurements and angiogenesis assays. Key Results: M Phi accumulated within the CNV of murine nAMD models and expressed high levels of glycolysis-related enzymes and M1/M2 polarization markers. This phenotype of hyper-glycolytic and activated M Phi was replicated in bone marrow-derived macrophages stimulated by necrotic RPE in vitro. Myeloid cell- specific knockout of PFKFB3, a key glycolytic activator, attenuated pathological neovascularization in laser-induced CNV, which was associated with decreased expression of M Phi polarization markers and pro-angiogenic factors, along with decreased sprouting of vessels in choroid/RPE complexes. Mechanistically, necrotic RPE increased PFKFB3-driven glycolysis in macrophages, leading to activation of HIF-1 alpha/HIF-2 alpha and NF-kappa B, and subsequent induction of M1/M2 markers and pro-angiogenic cytokines, finally promoting macrophage reprogramming towards an angiogenic phenotype to facilitate development of CNV. The PFKFB3 inhibitor AZ67 also inhibited activation of HIF-1 alpha/HIF-2 alpha and NF-kappa B signalling and almost completely prevented laser-induced CNV in mice. Conclusions and Implications: Modulation of PFKFB3-mediated macrophage glycolysis and activation is a promising strategy for the treatment of nAMD.

PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Inflammatory Machenism in the Pathogenesis of Diabetic Retinopathy

Vascular endothelial growth factor in eye disease

PFKFB3: A Potential Key to Ocular Angiogenesis

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

[Research Advances of Platelet Derived Growth Factor Family and Its Significance in Neovascular Eye Diseases].

Vascular endothelial growth factor and intraocular neovascularization

Anti-VEGF therapy in pediatric retinal and choroidal disease

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Molecules related to diabetic retinopathy in the vitreous and involved pathways

PGF2α Facilitates Pathological Retinal Angiogenesis by Modulating Endothelial FOS‐driven ELR + CXC Chemokine Expression

Progression and Challenge of Anti-Vascular Endothelial Growth Factor Therapy in Retinal Neovascular Disease

Neurovascular regulation in diabetic retinopathy and emerging therapies

Suppression of Myeloid PFKFB3‐driven Glycolysis Protects Mice from Choroidal Neovascularization

Targeting FSCN1 with an Oral Small-Molecule Inhibitor for Treating Ocular Neovascularization.

The mechanism of EGFL7 regulating neovascularization in diabetic retinopathy through the PI3K/AKT/VEGFA pathway

[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]

Understanding the pathogenesis of various type in exudative AMD, using the rational therapy

[The Rational Use of Anti-Vascular Endothelial Growth Factor Drugs to Assist the Treatment of Diabetic Retinopathy].

Pericyte in retinal vascular diseases: A multifunctional regulator and potential therapeutic target